UK biotech MitoRx Therapeutics has announced appointments, with Christine Charman named as chief development officer, David Richardson as finance director, and four appointments to its Scientific Advisory Board (SAB): Prof Chas Bountra, Prof Dame Kay Davies, Prof Laurent Servais, and Dr Bernd Schwahn.
MitoRx) is a biotechnology company developing revolutionary therapeutics that reverse mitochondrial dysfunction to arrest the progression of degenerative diseases,
Christine Charman comes with close to 26 years’ experience in accelerating transformational therapies as senior global program lead for Takeda’s (TYO: 4502) rare diseases, respiratory and immunology and neuroscience therapy areas. She also worked as consultant CDO at Izana Bioscience and development consultant for a range of biotechs and newcos and program lead supporting UK Vaccine and Antiviral Task Forces, with further development experience at Novartis (NOVN: VX) from pre-clinical research leadership to senior global program Director, including the planning, clinical execution and launch of two products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze